tetano
Editor, Senior Moderator
Health Sci Rep
. 2022 Apr 13;5(3):e572.
doi: 10.1002/hsr2.572. eCollection 2022 May.
The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan
Yudai Kaneko[SUP] 1 2 [/SUP], Akira Sugiyama[SUP] 1 3 [/SUP], Toshiya Tanaka[SUP] 1 [/SUP], Kazushige Fukui[SUP] 3 [/SUP], Akashi Taguchi[SUP] 1 [/SUP], Kenji Tatsuno[SUP] 1 [/SUP], Aya Nakayama[SUP] 3 [/SUP], Kazumasa Koga[SUP] 4 [/SUP], Yoshiro Kishi[SUP] 2 [/SUP], Wang Daming[SUP] 5 [/SUP], Chungen Qian[SUP] 6 [/SUP], Fuzhen Xia[SUP] 7 [/SUP], Fan He[SUP] 7 [/SUP], Liang Zheng[SUP] 7 [/SUP], Yi Yu[SUP] 7 [/SUP], Youichiro Wada[SUP] 1 3 [/SUP], Yoshiaki Wada[SUP] 4 [/SUP], Tatsuhiko Kodama[SUP] 1 [/SUP], Takeshi Kawamura[SUP] 1 3 [/SUP]
Affiliations
Abstract
Background: We compared the temporal changes of immunoglobulin M (IgM), IgG, and IgA antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (N), spike 1 subunit (S1), and receptor-binding domain (RBD), and neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with coronavirus disease 2019 (COVID-19) to understand the humoral immunity in COVID-19 patients for developing drugs and vaccines for COVID-19.
Methods: A total of five confirmed COVID-19 cases in Nissan Tamagawa Hospital in early August 2020 were recruited in this study. Using a fully automated chemiluminescence immunoassay analyzer, we measured the levels of IgG, IgA, and IgM against SARS-CoV-2 N, S1, and RBD and NAbs against SARS-CoV-2 in COVID-19 patients' sera acquired multiple times in individuals from 0 to 76 days after symptom onset.
Results: IgG levels against SARS-CoV-2 structural proteins increased over time in all cases but IgM and IgA levels against SARS-CoV-2 showed different increasing trends among individuals in the early stage. In particular, we observed IgA increasing before IgG and IgM in some cases. The NAb levels were more than cut-off value in 4/5 COVID-19 patients some of whose antibodies against RBD did not exceed the cut-off value in the early stage. Furthermore, NAb levels against SARS-CoV-2 increased and kept above cut-off value more than around 70 days after symptom onset in all cases.
Conclusion: Our findings indicate COVID-19 patients should be examined for IgG, IgA, and IgM against SARS-CoV-2 structural proteins and NAbs against SARS-CoV-2 to analyze the diversity of patients' immune mechanisms.
Keywords: COVID‐19; SARS‐CoV‐2; antibody; neutralizing antibody; patient.
. 2022 Apr 13;5(3):e572.
doi: 10.1002/hsr2.572. eCollection 2022 May.
The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan
Yudai Kaneko[SUP] 1 2 [/SUP], Akira Sugiyama[SUP] 1 3 [/SUP], Toshiya Tanaka[SUP] 1 [/SUP], Kazushige Fukui[SUP] 3 [/SUP], Akashi Taguchi[SUP] 1 [/SUP], Kenji Tatsuno[SUP] 1 [/SUP], Aya Nakayama[SUP] 3 [/SUP], Kazumasa Koga[SUP] 4 [/SUP], Yoshiro Kishi[SUP] 2 [/SUP], Wang Daming[SUP] 5 [/SUP], Chungen Qian[SUP] 6 [/SUP], Fuzhen Xia[SUP] 7 [/SUP], Fan He[SUP] 7 [/SUP], Liang Zheng[SUP] 7 [/SUP], Yi Yu[SUP] 7 [/SUP], Youichiro Wada[SUP] 1 3 [/SUP], Yoshiaki Wada[SUP] 4 [/SUP], Tatsuhiko Kodama[SUP] 1 [/SUP], Takeshi Kawamura[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35509410
- PMCID: PMC9059222
- DOI: 10.1002/hsr2.572
Abstract
Background: We compared the temporal changes of immunoglobulin M (IgM), IgG, and IgA antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (N), spike 1 subunit (S1), and receptor-binding domain (RBD), and neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with coronavirus disease 2019 (COVID-19) to understand the humoral immunity in COVID-19 patients for developing drugs and vaccines for COVID-19.
Methods: A total of five confirmed COVID-19 cases in Nissan Tamagawa Hospital in early August 2020 were recruited in this study. Using a fully automated chemiluminescence immunoassay analyzer, we measured the levels of IgG, IgA, and IgM against SARS-CoV-2 N, S1, and RBD and NAbs against SARS-CoV-2 in COVID-19 patients' sera acquired multiple times in individuals from 0 to 76 days after symptom onset.
Results: IgG levels against SARS-CoV-2 structural proteins increased over time in all cases but IgM and IgA levels against SARS-CoV-2 showed different increasing trends among individuals in the early stage. In particular, we observed IgA increasing before IgG and IgM in some cases. The NAb levels were more than cut-off value in 4/5 COVID-19 patients some of whose antibodies against RBD did not exceed the cut-off value in the early stage. Furthermore, NAb levels against SARS-CoV-2 increased and kept above cut-off value more than around 70 days after symptom onset in all cases.
Conclusion: Our findings indicate COVID-19 patients should be examined for IgG, IgA, and IgM against SARS-CoV-2 structural proteins and NAbs against SARS-CoV-2 to analyze the diversity of patients' immune mechanisms.
Keywords: COVID‐19; SARS‐CoV‐2; antibody; neutralizing antibody; patient.